Share ideas that matter on the social web and experience
the benefits of curating the world's best content.
I don't have a Facebook, a Twitter or a LinkedIn account
 Your new post is loading...
Scoop.it!
US biopharmaceutical companies are currently developing 465 new medicines that target the 10 leading chronic conditions affecting people aged 65 and over, according to new industry data. The medicines, which are all now in clinical trials or under review by the Food and Drug Administration (FDA), are diverse in scope, notes the Pharmaceutical Research and Manufacturers of America (PhRMA), which has published the data. (...) - by Lynne Taylor, PharmaTimes, March 22, 2013 Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
Pharmaceutical companies lose an estimated $188 billion annually in revenues in the U.S. because patients fail to take their prescribed medications, according to a study by consulting firm Capgemini.
Even for the countries in Western Europe such as the Netherlands where medication is fully covered, adherence is still a major concern and growing issue.
In the U.S. Medicare payment reforms aim to place an emphasis on preventive health measures affecting other sectors in health care, pharmaceutical companies are no longer alone in facing poor medication adherence.
The question is are these false promises or actual achievable objectives because of wrong targeting?
Via OMP Digital, Lionel Reichardt / le Pharmageek, Rémy TESTON, Pharmacomptoir / Corinne Thuderoz Delete the scoop?
Are you sure you want to delete this scoop?
Yes
|
Scoop.it!
In recent months, Alzheimer’s compounds have been hot news. Pfizer and Johnson & Johnson had one that flopped. Eli Lilly released mixed study results that generated a mix of hype and hope. And Merck (back stories here, here and here). And Merck is betting on one in a test with patients suffering mild to moderate symptoms. Meanwhile, another big drugmaker, Roche, is chugging along with a few compounds of its own and hopes its focus on early-stage disease will prove correct. We spoke briefly with Luca Santarelli, the head of neuroscience at Roche, about its efforts… (...) - Pharmalot, By Ed Silverman, December 11th, 2012
Delete the scoop?
Are you sure you want to delete this scoop?
Yes
|
Interesting, also in light of the Dutch IEMO project which aims at including seniors in clinical trials to measure the effect durgs have have on them.